Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
A positive dose-response relationship of daily walking duration with quartiles of SHBG was seen after adjustment for age, sex, history of cardiovascular diseases, diabetes, smoking, γ-glutamyl transferase, and C-reactive protein (p for trend = .010).
|
30676188 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, participants with CVD had significantly higher central SBP and AIx@75 compared with those without CVD.
|
29049227 |
2017 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Adjusted cubic spline analysis showed significant nonlinear but different association between SBP and CVD mortality among diabetes mellitus (U-shaped) and NON-DM (J-shaped).
|
28800042 |
2018 |
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
AGHD = adult growth hormone deficiency; ASCVD = atherosclerotic cardiovascular disease; AUROC = area under the receiver operating characteristic curve; BMI = body mass index; CVAI = Chinese visceral adiposity index; CVD = cardiovascular disease; DBP = diastolic blood pressure; GH = growth hormone; GHRT = GH replacement therapy; HDL-C = high-density lipoprotein cholesterol; IGF-1 = insulin like factor-1; IGFBP-3 = insulin like factor binding protein-3; IR = insulin resistance; LAP = lipid accumulation product; MS = metabolic syndrome; SBP = systolic blood pressure; TC = total cholesterol; TG = triglycerides; VAI = visceral adiposity index; WC = waist circumference; WHR = waist-to-hip ratio.
|
29144802 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Background Both sex hormone-binding globulin and central obesity have been found to be associated with metabolic and cardiovascular diseases.
|
29770358 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Distinguishing trajectories allows identification of subgroups at risk of hypertension and cardiovascular disease later in life and in addition can inform the design of targeted interventions to attenuate high SBP and DBP trajectories over time and maintain normal trajectories.
|
28234673 |
2017 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Eligible participants (N = 50, mean age 74 ± 7 years, 34% men, 26% with history of cardiovascular disease) had higher SBP during the anesthesiologic than the cardiological evaluation (157 ± 23 vs. 144 ± 18 mmHg, P < 0.001), and the former levels were almost identical to those clinically measured just before surgery.
|
30950973 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Epidemiological studies reported an inconsistent association between stage 1 hypertension (SBP 130-139 mmHg or DBP 80-89 mmHg) defined by the 2017 American College of Cardiology/American Heart Association hypertension guidelines and cardiovascular disease (CVD) events.
|
31790053 |
2020 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, CR decreased blood pressure (SBP -8 ± 3 mmHg, P = 0.005; DBP -6 ± 2 mmHg, P < 0.001), total cholesterol (-13.6 ± 5.3 mg/dl, P = 0.001), and LDL-cholesterol (-12.9 ± 4.4 mg/dl, P = 0.005), and the 10-yr risk of CVD-disease was reduced by 30%.
|
29351490 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
However, for patients with protein-creatinine ratio >500 mg/g (albumin-creatinine ratio > 300 mg/g), with or without diabetes, lower SBP target should be proposed for renal protection aiming SBP < 130 mmHg as recommended by KDIGO guidelines.In patients at low or intermediate risk, without cardiovascular disease, SBP should start to be treated when SBP is above 140 mmHg, and when treated, target BP should be less than 140 mmHg as reported by HOPE-3 trial.
|
27722961 |
2017 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
If SBP was more than 140 mmHg, treatment reduced all-cause and cardiovascular mortality, cardiovascular disease, stroke, myocardial infarction and heart failure.
|
27870655 |
2017 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
If identified, such changes may have important clinical relevance, particularly, as low sex hormone binding globulin (SHBG) and follicle stimulating hormone (FSH) are known to promote metabolic and cardiovascular disease in women.
|
30339729 |
2019 |
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In a prospective cohort study, we evaluated baseline levels of SHBG, T, and DHT using liquid chromatography-tandem mass spectrometry among 852 men free of diabetes and cardiovascular disease in the Cardiovascular Health Study in 1994.
|
27732332 |
2017 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, both ambulatory SBP and DBP were independently associated with CVD.
|
28422891 |
2017 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In middle-age, SBP in both races identified risk of incident CVD.
|
28199497 |
2017 |
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In the dipping group, only night-day ratio of SBP was significantly associated with CVD, with an odds ratio (OR) of 1.09 (95% confidence interval (CI) of 1.02-1.34).
|
30899285 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Investigate relations of mass spectrometry-assessed estrone (E1), E2, and T and SHBG and subclinical CVD in women.
|
29788255 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Linear, logistic, and Cox regression models assessed the association of top quartiles (P75) of serum testosterone, free androgen index (FAI), dehydroepiandrosterone, and androstenedione and sex hormone-binding globulin with coronary artery calcium, carotid intima-media thickness (IMT), pulse wave velocity, peripheral artery disease, and incidence of coronary heart disease (CHD), stroke, and CVD.
|
29408955 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Low plasma sex hormone-binding globulin (SHBG) levels in overweight individuals are a biomarker for the metabolic syndrome and are predictive of type 2 diabetes and cardiovascular disease risk.
|
26441241 |
2015 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Low serum Sex Hormone-Binding Globulin (SHBG) has been proposed as an indicator of the Metabolic Syndrome (MS) and cardiovascular disease in men.
|
20690069 |
2011 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
LHGDN |
Low sex hormone-binding globulin is associated with low high-density lipoprotein cholesterol and metabolic syndrome in women with PCOS.
|
16757555 |
2006 |
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Measurements of SHBG are widely used to predict plasma free testosterone levels in patients suffering from excess androgen exposures, but have broader utility in assessing the risk for endocrine diseases and clinical sequelae of the metabolic syndrome, namely, type 2 diabetes and cardiovascular disease.
|
22531107 |
2012 |
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Median HbA<sub>1c</sub> overall was 55 mmol/mol (7.2%), median SBP was 132 mmHg, median total cholesterol was 4.1 mmol/l and mean BMI was 32 kg/m<sup>2</sup><sub>.</sub> Overall two-thirds (65% of men, 68% of women) have two or more of the following CVD risk factor thresholds: HbA<sub>1c</sub> ≥ 53 mmol/mol (7%), SBP > 130 mmHg or DBP > 80 mmHg, total cholesterol ≥ 5 mmol/l or BMI ≥ 30 kg/m<sup>2</sup> , or were currently smoking.
|
30246473 |
2019 |
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
MRI-derived subclinical HFF is associated with SBP and DBP as well as with hypertension in participants from the general population without history of cardiovascular disease.
|
28253218 |
2017 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Neither SHBG nor TT was significantly associated with all-age CVD mortality [hazard ratio (HR), 0.69; 95% CI, 0.29 to 1.63; P = 0.40; and HR, 0.60; 95% CI, 0.28 to 1.26; P = 0.18, respectively].
|
31390027 |
2019 |